Currently just one class of drugs is recommended for the treatment of patients with heart failure with mildly reduced or preserved ejection fraction: the SGLT2 inhibitors, namely Jardiance and Farxiga. Data presented at the annual congress of the European Society of Cardiology in London on 1 September could change that.
Key Takeaways
- In the FINEARTS-HF trial, Bayer’s Kerendia reduced the risk of cardiovascular death and heart failure events by 16% over placebo.
Full data from the FINEARTS-HF trial of Bayer AG’s Kerendia (finerenone), toplined a hit last month, shows that the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
